NCT07565987Not yet recruiting
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
The APRIL Trial: A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 5 Dec 2022
- Start date
- 19 Dec 2026
- Primary completion date
- 18 Dec 2029
- Lead sponsor
- All India Institute of Medical Sciences
- Diseases
- Lung cancer
- NCT number
- NCT07565987
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 19 Dec 2026 to the primary completion date, 18 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy to thorax.
- Patients on anticoagulant therapy \& ultra-central cavitary tumors.
Other illness
- Metastatic disease.
Age
- Age\< 18 or \> 75 years.
Other
- Tumor size \> 6cm.
- Involved Lymph node size greater than 4 cms \& more than 3 station of lymph nodes involved.
- Patients with superior vena cava obstruction.
- Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium.
- Small cell histology.
- Poor performance status ECOG 2-3.
- Immunocompromised states.
- Viral Markers negative.
- Pregnant women
Who the study is looking for
- Aged 18 or above and less than 75 years.
- Histologically proven non-small cell lung cancer.
- Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms.
- ECOG status 0-1.
- Available to attend long term follow- up.
- Written informed consent for treatment.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nci, Aiims-Jhajjar Coordinator of this site? Confirm its status | Jhajjar | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.